Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives $11.89 Consensus Price Target from Brokerages

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has earned an average rating of “Buy” from the eleven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have given a buy rating and four have given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $11.7778.

CATX has been the topic of a number of recent analyst reports. B. Riley dropped their price target on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday. BTIG Research initiated coverage on Perspective Therapeutics in a research note on Friday, October 10th. They issued a “buy” rating and a $14.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, November 11th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a research report on Friday, October 3rd.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds have recently added to or reduced their stakes in CATX. Russell Investments Group Ltd. grew its stake in Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at $46,000. Ground Swell Capital LLC purchased a new position in shares of Perspective Therapeutics in the 2nd quarter worth $56,000. Los Angeles Capital Management LLC purchased a new stake in shares of Perspective Therapeutics during the 2nd quarter worth about $61,000. Finally, MetLife Investment Management LLC raised its holdings in Perspective Therapeutics by 40.9% in the first quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock valued at $67,000 after buying an additional 9,082 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Trading Up 0.9%

Shares of NYSEAMERICAN:CATX opened at $2.30 on Friday. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $6.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 15.09 and a current ratio of 15.09. The firm has a 50 day simple moving average of $3.18 and a 200-day simple moving average of $3.31.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.02). Perspective Therapeutics had a negative net margin of 7,688.50% and a negative return on equity of 33.37%. The firm had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.21 million. On average, research analysts expect that Perspective Therapeutics will post -0.88 EPS for the current year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.